Magnetar Financial LLC Buys 82,542 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Magnetar Financial LLC increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 324.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 107,962 shares of the biotechnology company’s stock after acquiring an additional 82,542 shares during the period. Magnetar Financial LLC’s holdings in BioCryst Pharmaceuticals were worth $967,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in BCRX. Alkeon Capital Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 1.7% in the 1st quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company’s stock worth $54,105,000 after purchasing an additional 120,199 shares in the last quarter. Geode Capital Management LLC lifted its position in BioCryst Pharmaceuticals by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company’s stock worth $45,296,000 after buying an additional 93,973 shares during the last quarter. Millennium Management LLC boosted its stake in BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock worth $28,597,000 after buying an additional 3,022,769 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in BioCryst Pharmaceuticals by 25,631.2% in the second quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock worth $32,441,000 after buying an additional 3,606,566 shares in the last quarter. Finally, Jupiter Asset Management Ltd. grew its position in BioCryst Pharmaceuticals by 82.4% during the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company’s stock valued at $16,117,000 after acquiring an additional 971,040 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 0.9%

BCRX stock opened at $6.97 on Monday. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -38.72 and a beta of 1.09. The firm’s 50-day moving average price is $7.22 and its two-hundred day moving average price is $8.53. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.00 and a 12-month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). The company had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. During the same quarter in the previous year, the firm earned ($0.07) earnings per share. BioCryst Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Evercore ISI restated an “in-line” rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research note on Wednesday, October 15th. TD Cowen began coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target for the company. Citizens Jmp decreased their price objective on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, November 5th. Finally, Needham & Company LLC lowered their target price on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.